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Introduction: Dendritic cells (DC) are the most potent antigen-presenting cells of the immune system, involved in
both initiating immune responses and maintaining tolerance. Dysfunctional and via toll-like receptor (TLR) ligands
activated DC have been implicated in the development of autoimmune diseases, but their role in the etiology of
Sjögren’s syndrome, a chronic inflammatory autoimmune disease characterized by progressive mononuclear cell
infiltration in the exocrine glands, has not been revealed yet. Therefore, the aim of this study was to investigate
phenotype and functional properties of immature and TLR7/8 stimulated monocyte-derived DC (moDC) of patients
with primary Sjögren’s syndrome (pSS) and compare them to healthy controls.
Methods: The phenotype, apoptosis susceptibility and endocytic capacity of moDC were analyzed by flow
cytometry. Secretion of cytokines was measured by enzyme-linked immunosorbent assay (ELISA) and multiplex
Luminex analyses in moDC cell culture supernatants. The expression of TLR7 was analyzed by flow cytometry and
real-time quantitative polymerase chain reaction (qPCR). Expression of Ro/Sjögren’s syndrome-associated autoantigen A
(Ro52/SSA), interferon regulatory factor 8 (IRF-8), Bim, signal transduction and activators of transcription (Stat) 1, p-Stat1
(Tyrosin 701), p-Stat1 (Serin 727), Stat3, pStat3 (Tyrosin 705) and glyceraldehyde 3-phosphatase dehydrogenase
(GAPDH) was measured by Western blotting. Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)
family members were quantified using the ELISA-based TransAM NF-κB family kit.
Results: We could not detect differences in expression of co-stimulatory molecules and maturation markers such
as cluster of differentiation (CD) 86, CD80, CD40 or CD83 on moDC from patients compared to healthy controls.
Moreover, we could not observe variations in apoptosis susceptibility, Bim and Ro52/SSA expression and the
endocytic capacity of the moDC. However, we found that moDC from pSS patients expressed increased levels of
the major histocompatibility complex (MHC) class II molecule human leukocyte antigen (HLA)-DR. We also found
significant differences in cytokine production by moDC, where increased interleukin (IL)-12p40 secretion in mature
pSS moDC correlated with increased RelB expression. Strikingly, moDC from pSS patients matured for 48 hours
with TLR7/8 ligand CL097 expressed significantly less Stat1.
Conclusion: Our results suggest a role for moDC in the pathogenesis of Sjögren’s syndrome.* Correspondence: petra.vogelsang@k2.uib.no
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Sjögren’s syndrome (SS) is a chronic, inflammatory auto-
immune disease characterized by progressive mononuclear
cell infiltration in the salivary and lacrimal glands of mainly
T cells but also B cells and dendritic cells (DC) [1]. Patients
with primary Sjögren’s syndrome (pSS) suffer from dryness
of the mouth (xerostomia) and eyes (keratoconjunctivitis
sicca), whereas in patients with secondary SS the symp-
toms occur in combination with other related rheumatic
autoimmune diseases.
Serological characteristics of systemic autoimmune
diseases such as SS are the production of autoantibodies
and a skewed profile of several cytokines. Notably, type I
interferon (IFN) alpha has been strongly related to SS
and systemic lupus erythematosus (SLE) [2], and upreg-
ulation of IFN-regulated genes in salivary glands [3-5]
and monocytes [6] has been described previously in pa-
tients with SS. In response to IFN, the transcription factor
Stat1 becomes activated via phosphorylation on tyrosine
(Y701) and serine (S727) residues and directs transcrip-
tion of IFN-regulated genes [7].
Intriguingly, many autoantibodies associated with auto-
immune diseases are directed towards cellular nuclear
components. Defective binding of self-molecules to toll-
like receptor (TLR) and inadequate activation of antigen-
presenting cells (APCs) might thus be the trigger for the
aberrant immune activation seen in autoimmune patients
[8]. In patients with SS, frequently found autoantibodies
are directed towards Ro/SSA, consisting of Ro52/SSA and
Ro60/SSA, as well as La/SSB. These autoantibodies can
even be detected in many patients long before the onset of
symptoms [9]. Ro52/SSA has been identified as an E3
ubiquitin ligase, which among others can ubiquitinate
members of the interferon regulatory factor (IRF) family
[10,11]. One target of Ro52/SSA was found to be IRF-8,
a transcription factor that is important for both the devel-
opment of DC and expression of cytokines such as IFN
[12,13]. IRFs become activated after stimulation with TLR
ligands, and thus autoantibodies against Ro52/SSA might
indirectly influence the transcription of both type I IFN
and IFN-inducible genes. This might be of importance
as several studies have suggested a central role for DC
and type I IFN in the pathogenesis of autoimmune dis-
eases [14].
DC are key players in both initiating an immune re-
sponse and maintaining tolerance [15,16]. During the
development from antigen-capturing cells to APCs, DC
undergo a maturation process characterized by morpho-
logical and phenotypical changes, involving loss of endo-
cytic capacity as well as upregulation of molecules such
as CD40, CD80, CD83 and CD86, which are important
molecules for priming of naïve T cells [17].
DC comprise a heterogeneous population of cells, which
in humans is divided into two main subsets, myeloid DCand the type I IFN-producing plasmacytoid DC [18,19].
DC populations are relatively rare in blood, but in vitro
generated monocyte-derived dendritic cells (moDC) are
functional APCs that also develop from monocytes under
inflammatory conditions in the body and thus are a useful
tool to study DC functions ex vivo [20].
The breakdown of peripheral tolerance in autoimmune
patients might be a result of defective DC. In patients
with SLE, DC have been shown to overexpress CD86
and might therefore be overactive in stimulating T cells
[21,22]. Furthermore, the lifespan and apoptosis suscep-
tibility of DC might influence the duration of activating
T cells and consequently controlling immune responses,
as transgenic mice with DC defective in apoptosis eventu-
ally develop systemic autoimmune manifestations [23,24].
In particular, the proapoptotic protein Bim and the antia-
poptotic protein Bcl-2 have been at the center of several
investigations since they have been shown to control the
lifespan of DC [24,25]. Despite their pivotal role in toler-
ance maintenance, few functional and phenotypical stud-
ies have so far been performed with DC from patients
with pSS. It has been proposed that an initial viral infec-
tion might trigger the onset of autoimmune diseases by
increasing cytokine production in response to TLR activa-
tion [26]. We therefore chose the TLR7/8 ligand CL097 as
a maturation stimulus in our study, because it mimics
viral single-stranded RNA components.
The aim of this study was to investigate possible de-
fects in moDC of patients with pSS. Our results showed
that these cells are phenotypically similar and have a
normal endocytic capacity compared with moDC from
healthy controls, although they express higher amounts
of surface HLA-DR and CCR7 molecules. Moreover, these
cells differ from normal control cells in secretion of sev-
eral cytokines (interleukin (IL)-7, IL-12p40, tumor necro-
sis factor alpha (TNFα), IFN gamma and macrophage
inflammatory protein (MIP)-1α). Elevated IL-12p40 secre-
tion correlated with increased nuclear RelB expression in
cells stimulated for 48 hours with TLR7/8 ligand CL097.
Additionally, mature moDC from pSS patients had signifi-
cant lower proportions of Stat1 and p-Stat1 compared
with healthy controls, suggesting that moDC might con-
tribute to the pathogenic events seen in patients with pSS.
Methods
Patient samples
In total, 52 pSS patients and 55 controls were included in
this study (Table 1). Owing to restricted numbers of
moDC generated from limited amounts of fresh blood ob-
tained for patients and controls, not all experiments could
be performed for all samples. Numbers of samples used
for the individual experiments are indicated in the figure
legend. All patients fulfilled the American–European Con-
sensus group criteria for classification of SS [27] and were
Table 1 Characteristics of patient and control cohort used
in this study
Sjögren’s syndrome Healthy controls
Number 52 55
Age (years)
Mean ± standard deviation 58 ± 13 52 ± 8
Range 20 to 81 38 to 68
Female:male 51:1 53:2
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University Hospital, Bergen, Norway. Gender-matched
and age-matched healthy controls were obtained from
the Bloodbank at the Haukeland University Hospital.
The study was approved (# 242.06) by the ethical com-
mittee of the University of Bergen, Norway. All studied
subjects gave their informed consent.
Preparation and maturation of monocyte-derived
dendritic cells
For generation of moDC, 20 to 45 ml heparinized blood
were collected from each participant and handled within
2 hours. Peripheral blood mononuclear cells were iso-
lated by discontinuous gradient centrifugation using
Lymphoprep (Axis Shield PoC AS, Oslo, Norway) and
monocytes isolated by plastic adherence in X-VIVO 20
(Lonza, Verviers, Belgium). Nonadherent cells were re-
moved after 1 hour of incubation at 37°C and 5% carbon
dioxide. Remaining monocytes were cultured in RP10
medium (RPMI 1640 with Ultraglutamine (Bio Whittaker,
Lonza), 10% FCS Gold (PAA, Pasching, Austria), 1%
penicillin–streptomycin (Gibco, Invitrogen Corporation,
Paisley, UK)) supplemented with 100 ng/ml granulo-
cyte–macrophage colony-stimulating factor (GM-CSF;
ImmunoTools GmbH, Friesoythe, Germany) and 20 ng/
ml IL-4 (ImmunoTools GmbH). Cytokines were replen-
ished every 2 or 3 days. After 5 to 6 days in culture, mat-
uration was induced in one part of the moDC by adding
1 μg/ml TLR7/8 ligand CL097 (InvivoGen, San Diego,
CA, USA) for 48 hours.
Immunostaining
Phenotypic characterization of moDC was performed
using mouse anti-human CD14-fluorescein isothiocyan-
ate (FITC), CD1a-phycoerythrin (PE), CD86-FITC and
CD80-APC antibodies (all from ImmunoTools GmbH),
HLA-DR-APC, CD83-PE, CD40-FITC and CD38-APC
antibodies (all from AbD Serotec, Düsseldorf, Germany),
and CCR7-PE and TLR7-PE antibodies (R&D Systems,
Minneapolis, MN, USA). Detection of apoptosis was per-
formed using Annexin V–FITC (ImmunoTools GmbH) for
labeling of early apoptotic events and 7-AAD (eBioscience,
San Diego, CA, USA) for discrimination of necrotic and
dead cells. Cells were analyzed on a BD LRS Fortessa flowcytometer (BD Bioscience, San Jose, CA, USA) and data
analysis was performed with FlowJo software (Tree Star
Inc., Ashland, OR, USA). Both percentages of positive cells
and the median fluorescence intensity (MFI) in the control
sample were subtracted from either percentages of positive
cells or the MFI in the stained sample.Cytokine production
Cytokine concentrations were measured in cell-free su-
pernatants from immature and mature moDC cultures
using a commercially available human cytokine twenty-
five-plex kit (Biosource, Invitrogen Corporation, Carlsbad,
CA, USA) including IL-1β, IL-1RA, IL-2, IL-2R, IL-4, IL-
5, IL-6, IL-7, IL-8, IL-10, IL-12p40, IL-13, IL-15, IL-17,
TNFα, IFN alpha, IFN gamma, GM-CSF, MIP-1α, MIP-
1β, IP-10, MIG, Eotaxin, CCL5 (RANTES) and MCP-1.
Multiplex plates were analyzed using a Luminex 100 in-
strument with StarSection software (Applied Cytometry
Systems, Dinnington, UK). B-cell activating factor (BAFF)
levels were measured using the human BAFF/BLys/
TNFSF13B Quantikine enzyme-linked immunosorbent
assay (ELISA) Kit from R&D Systems. IL-4 and GM-
CSF in diluted samples as well as undiluted IL-12p70
levels were determined using ELISA Deluxe kits from
Biolegend (San Diego, CA, USA) according to the man-
ufacturer’s manual. IFN alpha was measured using the
Verikine human IFN alpha multi-subtype ELISA kit (PBL
Interferon Source, Piscataway, NJ, USA). All microtiter
plates were analyzed with an EMax microplate reader
(Molecular Devices, Sunnyvale, CA, USA).Real-time quantitative polymerase chain reaction
Total RNA was isolated from cell lysates using QIAGEN
RNeasy Mini anion-exchange spin columns (QIAGEN,
Hilden, Germany) according to the instructions of the
manufacturer. Then 100 ng total RNA were subjected to
a 20 μl cDNA synthesis reaction using RevertAid Re-
verse Transcriptase (Fermentas/Thermo Scientific, Oslo,
Norway). Oligo(dT)18 was used as primer. The cDNA
was diluted 1:2.5, and 5 μl were used in a 20 μl real-time
quantitative reverse transcriptase polymerase chain reac-
tion (PCR) using Taqman technology on an ABI PRISM
7500 Sequence Detection System (Applied Biosystems/
Invitrogen Dynal AS, Oslo, Norway). The primers/probes
utilized were: TLR7-FP, 5′-TGAATCTGTCAGGAAAT
CTCATTAGC; TLR7-RP, 5′-CAAGCCGGTTGTTGGA
GAAG; TLR7 probe, 5′-[6FAM] CAGTGAATTCCAACC
TTTAGCAGAGCTGAGATATT[BHQ1]; glyceraldehyde
3-phosphatase dehydrogenase (GAPDH)-FP, 5′-CCACAT
CGCTCAGACACCAT; GAPDH-RP, 5′-GGCAACAATA
TCCACTTTACCAGAGT; and GAPDH-probe, 5′-[6FA
M]ACCAAATCCGTTGACTCCGACCTTCA[TAMRA]
(all synthesized by Sigma-Aldrich, St Louis, MO, USA).
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For analysis of the endocytic capacity, 5 × 104 cells in
RP10 medium were incubated in a 96-well plate with or
without 0.25 mg/ml fluorescent dextran conjugate (FITC–
dextran, 40,000 MW; Molecular Probes, Invitrogen, Paisley,
UK) at 37°C. As a negative control, precooled cells were
incubated with FITC–dextran at 4°C. After 1 hour of incu-
bation, cells were washed for four times with phosphate-
buffered saline + 0.5% bovine serum albumin and were
analyzed immediately by flow cytometry.
Quantification of nuclear factor-κB family members
Nuclear factor (NF)-κB family members (p50, p65, c-Rel,
p52 and RelB) were quantified using the ELISA-based
TransAM NF-κB family kit (Active Motif, Rixensart,
Belgium) in whole protein lysates containing 10 μg pro-
tein per sample according to the manufacturer’s manual.
Microtiter plates were analyzed with an EMax micro-
plate reader (Molecular Devices).
SDS-PAGE and western blotting
Whole-cell lysates were prepared using RIPA buffer con-
taining 50 mM Tris, pH 7.4, 1% NP-40, 0.25% sodium
deoxycholate, 150 mM NaCl, 1 mM ethylenediamine tet-
raacetic acid, 1× proteinase inhibitor (Roche, Mannheim,
Germany), 1 mM phenylmethanesulfonyl fluoride, 1 mM
sodium-orthovanadate and 1 mM sodium fluoride. Then
10 μg protein per lane were loaded on SDS-polyacrylamide
gels and transferred onto nitrocellulose membranes. Che-
micals were purchased from Sigma Aldrich (Oslo, Norway)
if not otherwise stated. Membranes were probed with anti-
bodies against Ro52/SSA (sc-25351), IRF-8 (sc-6058), Bim
(sc-11425), Stat1 (sc-464), p-Stat1 Tyr701 (sc-7988), p-
Stat1 Ser727 (sc-16570), Stat3 (sc-482), pStat3 (sc-8059; all
antibodies purchased from Santa Cruz Biotechnology,
Santa Cruz, CA, USA), and GAPDH (clone 6C5; HyT-
est, Turku, Finland). Horseradish peroxidase-coupled
secondary antibodies were all from Bio-Rad Laborator-
ies (Hercules, CA, USA). Proteins were visualized and
quantified with a ChemiDOC XRS system and Quantity
One software (Bio-Rad Laboratories) using Super Signal
West Femto substrate (Pierce, Thermo Fisher Scientific,
Rockford, CA, USA). Expression levels were calculated
by measuring the density of the bands as a percentage in
relation to a standard sample used on all blots, which was
set to 100%, relative to GAPDH as loading control for
each sample. The results are shown as an arbitrary unit.
Statistical analyses
All statistical analyses were performed using Prism (Graph-
Pad Software Inc., La Jolla, CA, USA). When necessary,
datasets were analyzed with the D’Aostimo and Pearson
omnibus normality test to evaluate distribution of data.Since most of the data were not normally distributed, a
two-tailed nonparametric Mann–Whitney test was applied.
Results
Phenotypical characterization of moDC from patients with
pSS compared with healthy controls
Overexpression of co-stimulatory molecules such as
CD86 has been shown to affect moDC from patients
with SLE, an autoimmune disorder closely related to SS
[21,22]. We therefore decided to investigate the pheno-
type of moDC from patients with pSS (Figures 1 and 2).
Immature and mature cells from patients and healthy
controls were analyzed for expression of several surface
markers by flow cytometry (Figure 2). Neither the percent-
age of moDC positive for CD86 and CD80 (Figure 2C,G)
nor expression levels represented by the MFI revealed
significant variations between patients and controls
(Figure 2D,H). The percentage of mature moDC being
CD83-positive was higher in controls compared with
patients (Figure 2E), but expression levels of CD83 were
unaffected (Figure 2F). However, immature moDC and
moDC matured for 48 hours from pSS patients expressed
significantly higher levels of HLA-DR (Figure 2B) and
CCR7 (Figure 2J).
Apoptosis susceptibility and endocytic capacity of moDC
from patients with pSS are not altered compared with
healthy controls
Decreased apoptosis susceptibility in moDC might lead
to autoimmunity by enhancing the interaction between
DC and autoreactive T cells. To examine the apoptosis sus-
ceptibility of immature and mature moDC, we stained the
cells for the apoptosis marker Annexin V–FITC and the
necrosis marker 7-AAD, and analyzed them by flow cytom-
etry. We could not find differences in the amount of apop-
totic cells either among immature moDC or mature moDC
from pSS patients compared with controls (Figure 3A). We
further analyzed the expression of the proapoptotic protein
Bim in moDC by western blot. As expected, Bim expres-
sion was increased in mature moDC, but the expression
did not vary between moDC from patients and controls
(Figure 3B). We also compared the endocytic capacity
of immature and TLR7/8-matured moDC from pSS
patients and controls measuring the uptake of FITC-
labeled dextran by flow cytometry without finding sig-
nificant differences (Figure 3C).
Levels of TLR7 do not vary between moDC from pSS
patients and healthy controls
Since we used a TLR7/8 ligand to generate mature moDC
from pSS patients and controls, we analyzed TLR7 expres-
sion to exclude that possible variations in TLR7 expression
levels would influence our results. Using flow cytometry,
we did not detect significant differences in percentage of
Figure 1 Representative flow cytometry plots showing the monocyte-derived dendritic cell gate and histograms with isotype controls
for the presented markers (HLA-DR, CD86, CD83, CD80 and CCR7). The monocyte-derived dendritic cell (moDC) gate was set according to
scatter properties. Plots show isotype control IgG (open histogram) versus specific antibody staining (grey histogram). FSC, forward scatter; SSC,
side scatter.
Vogelsang et al. Arthritis Research & Therapy 2014, 16:R166 Page 5 of 12
http://arthritis-research.com/content/16/4/R166positive cells or MFI of TLR7 in immature moDC and
moDC matured for 48 hours between patients and con-
trols (Figure 4A,B). To further validate TLR7 levels on a
transcriptional level, we extracted RNA from moDC and
performed real-time quantitative PCR using TLR7-specific
primers and probe. Even though mature cells had reduced
amounts of TLR7 mRNA, levels of TLR7 transcripts did
not vary between immature and mature moDC from pSS
patients compared with controls (Figure 4C).
Levels of secreted cytokines by moDC from patients with
pSS differ significantly from healthy controls
Cytokine imbalances are often discussed in the context
of autoimmunity. To study whether these cytokines might
derive from moDC, we analyzed undiluted cell culture su-
pernatants from immature and matured moDC by ELISA
and 25-plex Luminex analyses. The concentration of most
cytokines was generally low, apart from IL-4 and GM-CSF
that were added to the cell culture to generate moDC. We
therefore reanalyzed IL-4 and GM-CSF levels in diluted
samples by ELISA, finding significantly lower levels of IL-4
in immature pSS samples compared with immature control
samples (mean ± standard deviation (pg/ml): P immature,11,595.9 ± 3,127.1; C immature, 9,590.8 ± 1,512.6). Using
25-plex Luminex analyses, we detected significant different
levels of IL-7, IL-12p40, TNFα, IFN gamma and MIP-1α in
mature moDC from pSS patients compared with controls
(Table 2). We found significantly decreased levels of the
chemokine of IL-7 and IFN gamma in mature moDC from
pSS patients compared with controls. Moreover, we found
that mature moDC from patients produced significant
higher levels of IL-12p40, TNFα and MIP-1α compared
with mature moDC from healthy controls. We further
tested the biologically active forms of IL-12p40, IL-12p70
and IL-23 by ELISA, but IL-23 was not secreted in detect-
able amounts while IL-12p70 was secreted only by mature
moDC without significantly altered levels (mean ± standard
deviation (pg/ml): P mature, 48.8 ± 68.7; C mature, 44.9 ±
82.0). BAFF, a cytokine that has been found to be upregu-
lated in plasma from patients with pSS [28], was measured
in moDC supernatants, showing that immature and mature
moDC from pSS patients secreted higher amounts of BAFF
compared with moDC from controls, but without reaching
statistical significance (mean ± standard deviation (pg/ml):
P immature, 41.8 ± 25.0; C immature, 31.3 ± 18.1; P mature,
38.5 ± 28.5; C mature, 28.6 ± 26.2). We also measured levels
Figure 2 (See legend on next page.)
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Figure 2 Expression of activation markers and co-stimulatory molecules in immature and mature monocyte-derived dendritic cells
from primary Sjögren’s syndrome patients and controls. For all samples, the percentage of positive cells or the median fluorescence intensity
(MFI) of the negative control was subtracted. Percentages of monocyte-derived dendritic cells (moDC) being positive for (A) HLA-DR, (C) CD86,
(E) CD83, (G) CD80 and (I) CCR7. MFI of the corresponding moDC for (B) HLA-DR, (D) CD86, (F) CD83, (H) CD80 and (J) CCR7. Primary Sjögren’s
syndrome patients, P immature n = 12 and P mature n = 10; controls, C immature n = 15 and C mature n = 11.
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tants by ELISA as IFNs play a crucial role in the develop-
ment of autoimmune diseases, without finding significant
amounts being secreted by moDC (data not shown).
Elevated levels of activated RelB correlate with increased
IL-12p40 secretion
To investigate possible factors involved in increased cyto-
kine secretion of moDC from pSS patients stimulated for
48 hours with a TLR7/8 ligand, we quantified activated
NF-κB family members (p50, p65, c-Rel, p52 and RelB)
using the ELISA-based TransAM NF-κB family kit. We
found that activated RelB is increased in mature moDC
from patients with pSS (Figure 5A), while none of the
other NF-κB family members being upregulated or down-
regulated (data not shown). IL-12p40 secretion was reana-
lyzed for the corresponding samples and quantified by
ELISA. The result confirmed previous multiplex data and
revealed increased levels in mature moDC from pSS pa-
tients (Figure 5B), without reaching the statistical signifi-
cance seen in multiplex analyses due to smaller sample
size. Nevertheless, samples with highest RelB expression
correlate to samples with highest IL-12p40 secretion.
Stat1 expression is significantly reduced in mature moDC
from patients with pSS compared with healthy controls
We next aimed to investigate protein expression levels
of the SS-related autoantigen Ro52/SSA in moDC, be-
cause increased mRNA levels of Ro52/SSA were foundFigure 3 Apoptosis susceptibility and endocytic capacity of monocyte
syndrome and healthy controls. (A) Percentage of monocyte-derived de
Primary Sjögren’s syndrome patients, P immature/mature n = 10; controls, C
measured by western blot. (C) Uptake of dextran–fluorescein isothiocyanat
controls, C immature n = 13 and C mature n = 13. MFI, median fluorescencein peripheral blood mononuclear cells from patients
with pSS. We also analyzed the expression levels of IRF-
8, a potential downstream target of Ro52/SSA, in moDC
from patients with pSS compared with healthy controls
by western blot. No differences in Ro52/SSA and IRF-8
protein expression in whole cell lysates from moDC be-
tween pSS patients and healthy controls could be ob-
served (data not shown).
To investigate possible altered signaling molecules on
protein level in moDC from pSS patients, we decided to
focus on members of the Stat signal transducer and
transcription factor family, as they are crucial for IFN
signaling. We compared unphosphorylated Stat1 and Stat3
as well as phosphorylated p-Stat1 (Y701), p-Stat1 (S727)
and p-Stat3 (Y705) in protein lysates from immature and
mature moDC. No differences in Stat3 and p-Stat3 levels
were detected in protein lysates of mature moDC from pa-
tients and controls (data not shown). However, we found
significantly reduced expression of Stat1α (91 kDa) in ma-
ture moDC from patients with pSS (Figure 6C), represen-
tative blots shown in Figure 6A,B. Stat1β (84 kDa) was
generally expressed at low levels, making a proper quanti-
fication difficult. We therefore restricted further analyses
to the full-length 91 kDa Stat1α isoform. We also analyzed
the amounts of phosphorylated Stat1 levels, and detected
significantly less p-Stat1 (S727) (Figure 6D) and reduced
p-Stat1 (Y701) (Figure 6E) in mature moDC from pSS
patients. Furthermore, we analyzed both IRF-1 and IRF-9
on a transcriptional level by real-time quantitative PCR,-derived dendritic cells from patients with primary Sjögren’s
ndritic cells (moDC) positive for Annexin V analyzed by flow cytometry.
immature/mature n = 16. (B) Expression of Bim in moDC samples
e (FITC) by moDC. Patients, P immature n = 19 and P mature n = 18;
intensity.
Figure 4 TLR7 expression in immature and mature monocyte-derived dendritic cells from primary Sjögren’s syndrome patients and
controls. (A) Percentage of monocyte-derived dendritic cells (moDC) positive for toll-like receptor 7 (TLR7) analyzed by flow cytometry. Primary
Sjögren’s syndrome (pSS) patients, P immature n = 18 and P mature n = 16; controls, C immature n = 16 and C mature n = 11. (B) Median
fluorescence intensity (MFI) of TLR7 in the corresponding moDC samples. (C) TLR7 on transcriptional level analyzed by real-time quantitative
polymerase chain reaction (qPCR) in moDC from pSS patients and controls. pSS, P immature n = 9 and P mature n = 6; controls, C immature
n = 14 and C mature n = 7. PE, phycoerythrin.
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ing cascade, without finding significant differences (data
not shown).
Discussion
In this study, we analyzed phenotypical and functional
properties of moDC from patients with pSS and compared
them with gender-matched and age-matched healthy con-
trols to elucidate whether DC might be involved in the
pathogenesis of SS. We discovered that moDC from pSS
patients express significantly increased levels of HLA-DR
and CCR7 and that mature moDC from pSS patients se-
crete altered amounts of several cytokines. Most of the an-
alyzed cytokines were detected at low levels, but two of
them (IL-12p40 and MIP-1α) were found in comparable
amounts also in serum samples from pSS patients [29].
Moreover, we found that increased IL-12p40 correlated
with increased amounts of nuclear RelB, indicating an
overactivated NF-κB pathway in mature moDC from pSS
patients. Furthermore, we found that moDC from pSS pa-
tients matured for 48 hours with a TLR7/8 ligand express
significantly less Stat1 compared with cells from healthyTable 2 Comparison of cytokines secreted by immature or TL
controls analyzed by multiplex Luminex analyses
Cytokine (pg/ml) Patients immature (n = 21) Controls immatur
IL-7 30.9 ± 11.0 35.3 ± 29.8
IL-12p40 703.9 ± 878.8 498.9 ± 362
IL-17 86.0 ± 22.1 83.2 ± 31.9
TNFα 28.9 ± 22.1 24.3 ± 8.8
Interferon gamma 18.3 ± 7.9 24.1 ± 12.5
MIP-1α 298.5 ± 138.8 304.3 ± 146
Only cytokines with a significant different value are shown. Data presented as mean
moDC, monocyte-derived dendritic cells; pSS, primary Sjögren’s syndrome; TLR, toll-like
and **P < 0.01) for the levels of six different cytokines was found when comparing macontrols. Stat1 is a signal transducer and transcription fac-
tor, which is especially important for the responsiveness to
IFN, but was also found to act as a suppressor of NF-κB
activation [30]. Decreased levels of Stat1 in mature moDC
from pSS patients might thus cause higher RelB activation
and eventually lead to elevated cytokine production.
Under inflammatory conditions, monocytes can turn
into inflammatory moDC, which can be generated in vitro
serving as an appropriate model for studying DC [31]. Mi-
gration of monocytes to the salivary glands, where they
turn into inflammatory moDC, has been proposed as a
possible source for DC found in the glands from SS pa-
tients [32]. The increase in CCR7 on mature moDC from
pSS patients might indicate that the homing to the lymph
node of these cells in response to the CCR7 ligands
CCL19 or CCL21 can be enhanced, but the general ex-
pression of CCR7 is relatively low, thus making a valid in-
terpretation rather difficult.
Immature DC are reckoned to mediate tolerance [33]
and overactive or preactivated DC have been suggested
to be involved in the development of autoimmune
diseases [34] via augmented activation of autoreactive TR7/8 stimulated mature moDC from pSS patients and
e (n = 17) Patients mature (n = 20) Controls mature (n = 16)
31.4 ± 11.0 40.3 ± 16.2*
.8 3847.9 ± 5867.8 796.3 ± 326.8**
76.6 ± 15.1 101.5 ± 39.4*
53.9 ± 20.5 39.8 ± 17.9*
20.5 ± 8.9 29.1 ± 9.3**
.5 398.7 ± 201.3 304.6 ± 228.5*
± standard deviation. IL, interleukin; MIP, macrophage inflammatory protein;
receptor; TNFα, tumor necrosis factor alpha. A significant difference (*P < 0.05
ture moDC from pSS patients with mature moDC from healthy controls.
Figure 5 Expression of activated RelB correlates to elevated secretion of IL-12p40. (A) Levels of RelB measured by the enzyme-linked
immunosorbent assay (ELISA)-based TransAM nuclear factor-κB family kit are slightly increased in mature monocyte-derived dendritic cells from
primary Sjögren’s syndrome patients (P mature, n = 11) compared with healthy controls (C mature, n = 11). (B) IL-12p40 secretion quantified by
ELISA in the same, corresponding samples is increased. OD, optical density.
Figure 6 Stat1 expression is significantly reduced in TLR7/8 stimulated monocyte-derived dendritic cells from primary Sjögren’s
syndrome patients. (A), (B) Representative western blots for Stat1α, p-Stat1α (Y701), p-Stat1α (S727) and glyceraldehyde 3-phosphatase
dehydrogenase (GAPDH) expression in mature monocyte-derived dendritic cells (moDC) from primary Sjögren’s syndrome (pSS) patients (n = 4)
and controls (n = 4). (C) Stat1 expression in immature and mature moDC from patients (n = 8) and controls (n = 8). (D) p-Stat1α (S727) expression
in immature and mature moDC from patients (n = 8) and controls (n = 8). (E) p-Stat1α (Y701) expression in immature and mature moDC from
patients (P immature n = 7 and P mature n = 8) and controls (C immature n = 5 and C mature n = 8). Relative expression levels are presented as
arbitrary units and were calculated as the percentage of band density normalized to GAPDH expression in relation to a standard sample used on
all blots (set to 100%).
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stimulatory molecules such as CD86 correlating with in-
creased disease activity has been described previously in
moDC of patients with SLE (reviewed in [35]). We found
increased levels of HLA-DR but not CD86 (Figure 2B,D),
clearly distinguishing moDC of SS patients from those of
SLE patients. An increase in HLA-DR expression indicates
that moDC from pSS patients are more active in antigen
presentation than moDC from controls, which might be
due to the fact that they derive from an inflammatory
environment. Interestingly, a strong association of SS with
genes encoding for HLA molecules has been reported, im-
plicating a genetic predisposition being associated with
the disease SS [36], and thus stressing the importance of
performing further studies on antigen-presenting func-
tions in these patients.
We also focused on cytokine profiles of immature and
mature moDC from pSS patients and controls and ana-
lyzed the cell culture supernatants by multiplex Luminex
analyses (Table 2). DC might be a possible source for cy-
tokines identified in serum from patients with pSS. We
detected significantly higher amounts of the proinflamma-
tory cytokines IL-12p40, TNFα, and MIP-1α in superna-
tants of mature moDC from pSS patients. Both IL-12p40
and MIP-1α levels correspond to amounts that have been
found in sera of pSS patients [29]. IL-12 is produced by
DC upon activation [37]. The biological active form of IL-
12 is a heterodimeric protein (IL-12p70) consisting of two
subunits, IL-12p40 and IL-12p35, directing immune re-
sponses towards Th1 cells. IL-12p40 can also be part of
IL-23 as a heterodimer with the IL-23p19 subunit. We
found significantly more IL-12p40 in supernatants from
TLR7/8-stimulated moDC from pSS patients compared
with controls, but we could not detect IL-23 in notable
amounts. IL-12p70 was secreted in small amounts by ma-
ture moDC, but without significant differences between
moDC from pSS patients compared with controls (data
not shown). Interestingly, a previous study reported ele-
vated serum titers of IL-12p40 in SS patients compared
with controls [38] and in comparable amounts with those
measured in this study. DC might therefore be the IL-
12p40-producing cells in patients with pSS. Although the
roles of the biological active forms of IL-12p40 are better
known, it was shown recently that IL-12p40 homodimers
attenuate regulatory T cells in mice [39]. Increased IL-
12p40 levels in pSS patients might therefore influence the
function of regulatory T cells and consequently prevent
peripheral tolerance due to suppression of regulatory T
cells. Apart from elevated IL-12p40 and MIP-1α levels, we
detected significantly increased levels of TNFα and de-
creased levels of IL-7 and IFN gamma in mature moDC of
pSS patients. Nevertheless, the amounts of those cytokines
were quite low in general, making the significance of the
results difficult to discuss. We also detected significantlyreduced IL-4 levels in immature pSS samples, but we can-
not conclude whether this difference occurred due to dif-
ferent secretion or consumption of moDC from pSS
patients because IL-4 was added to the cell culture.
To investigate signaling pathways being involved in al-
tered cytokine secretion of moDC from pSS patients
stimulated for 48 hours with a TLR7/8 ligand, we quan-
tified the activated NF-κB family members p50, p65, c-
Rel, p52 and RelB. Association of NF-κB genes with a
positive autoantibody titer was found in patients with
pSS previously [40]. Here we detected that expression of
activated RelB was increased in moDC from pSS pa-
tients. Samples with the highest RelB expression corre-
lated to samples with the highest IL-12p40 secretion,
pointing in the direction of enhanced signaling via an
activated NF-κB pathway.
To further investigate possible altered signaling mole-
cules in moDC from pSS patients, we investigated mem-
bers of the Stat signal transducer and transcription factor
family. The functions of activated Stat1 proteins are com-
plex since Stat1 drives expression of multiple genes, with
a key role in IFN signaling (reviewed in [41]). Although
the IFN signature seen in patients with pSS is rather asso-
ciated with plasmacytoid DC, systemic increase in type I
IFN might affect Stat1 pathways in other immune cells
such as moDC. Stat1 proteins become activated via phos-
phorylation on tyrosine (Y701) to initiate dimerization
and serine (S727) to fully develop transcriptional activity
in the nucleus. We found significantly lower protein levels
of Stat1α and p-Stat1 (S727) and lowered amounts of
p-Stat1 (Y701) and a visible reduction of Stat1β in mature
moDC from patients with pSS. Stat1 can act as a suppres-
sor of NF-κB activation [30] and therefore an increase in
activated RelB and IL-12p40 secretion can be a conse-
quence of altered Stat1 signaling, which might develop
under the influence of IFN. Because we used a TLR7/8 lig-
and to stimulate the moDC, we analyzed levels of TLR7
by flow cytometry and real-time quantitative PCR. No dif-
ferences were observed and thus our findings cannot be
explained by alterations in levels of TLR7.
This study emphasizes the importance of focusing on
studies of molecular mechanisms at the cellular level,
which indicate a possible dysfunction of DC contributing
to the inflammatory environment seen in autoimmunity.
Because Stat1 mRNA levels were not altered when
tested using real-time quantitative PCR, the mechanisms
behind the regulation of Stat1 proteins in mature moDC
need to be further investigated. It is of particular interest
to further elucidate the relation between Stat1 and the
IFN signature seen in patients with pSS by including the
analyses of plasmacytoid DC in these studies. Besides
analyzing different time points after DC stimulation, fur-
ther studies should include different stimuli, as our
study is limited to the TLR7/8 ligand CL097.
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Our data reveal a distinct decrease in Stat1 protein levels
in mature moDC from patients with pSS, possibly lead-
ing to increased activated nuclear RelB and consequently
elevated IL-12p40 secretion. These results indicate a de-
fect of mature moDC after activation by TLR7/8 ligand.
Furthermore, we found that immature and mature moDC
from pSS patients express more HLA-DR molecules com-
pared with healthy controls, a result that might build a
functional link to the genetic association with HLA-DR
genes seen in pSS patients. Expression of CCR7 is in-
creased in mature moDC from pSS patients, which could
lead to an increased homing ability of these cells. Since
this study is covering only a limited number of functional
analyses, we cannot totally rule out deficiencies in other
DC functions. In conclusion, we suggest that activated
moDC influence the pathogenesis of pSS via cytokine pro-
duction and propose further studies on Stat1 signaling,
Stat1 regulating mechanisms and antigen-presenting func-
tions to further elucidate the cause and function of de-
creased Stat1 and increased HLA-DR molecules.
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